company background image
0QYQ logo

Gilead Sciences LSE:0QYQ Stock Report

Last Price

US$69.78

Market Cap

US$86.8b

7D

-5.1%

1Y

-16.8%

Updated

06 Apr, 2024

Data

Company Financials +

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$69.78
52 Week HighUS$87.53
52 Week LowUS$68.55
Beta0.20
1 Month Change-5.16%
3 Month Change-16.82%
1 Year Change-16.83%
3 Year Change8.44%
5 Year Change6.90%
Change since IPO-18.35%

Recent News & Updates

Recent updates

Shareholder Returns

0QYQGB BiotechsGB Market
7D-5.1%-1.1%-0.5%
1Y-16.8%-29.8%0.4%

Rentabilidad frente al sector: 0QYQ superó al sector UK Biotechs , que obtuvo un rendimiento del -26.4% el año pasado.

Rentabilidad vs. Mercado: 0QYQ obtuvo unos resultados inferiores a los del mercado UK, que fue del -6.5% el año pasado.

Price Volatility

Is 0QYQ's price volatile compared to industry and market?
0QYQ volatility
0QYQ Average Weekly Movement3.9%
Biotechs Industry Average Movement7.2%
Market Average Movement4.9%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.6%

Precio estable de las acciones: El precio de las acciones de 0QYQ ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0QYQ (3%) se ha mantenido estable durante el año pasado.

About the Company

FoundedEmployeesCEOWebsite
198718,000Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc. es una empresa biofarmacéutica que descubre, desarrolla y comercializa medicamentos en áreas con necesidades médicas no cubiertas en Estados Unidos, Europa e internacionalmente. La empresa ofrece los productos Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs y Atripla para el tratamiento del VIH/SIDA; Veklury, una inyección para uso intravenoso, para el tratamiento del COVID-19; y Epclusa, Harvoni, Vemlidy y Viread para el tratamiento de la hepatitis vírica. También ofrece los productos Yescarta, Tecartus y Trodelvy para el tratamiento oncológico; Letairis, una formulación oral para el tratamiento de la hipertensión arterial pulmonar; y AmBisome, una formulación liposomal para el tratamiento de infecciones fúngicas invasivas graves.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
0QYQ fundamental statistics
Market capUS$86.76b
Earnings (TTM)US$5.67b
Revenue (TTM)US$27.12b

15.3x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QYQ income statement (TTM)
RevenueUS$27.12b
Cost of RevenueUS$6.02b
Gross ProfitUS$21.10b
Other ExpensesUS$15.43b
EarningsUS$5.67b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)4.54
Gross Margin77.80%
Net Profit Margin20.89%
Debt/Equity Ratio109.8%

How did 0QYQ perform over the long term?

See historical performance and comparison

Dividends

4.4%

Current Dividend Yield

66%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.